Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug884 | ChAdOx1 nCoV-19 0.5mL prime plus boost Wiki | 1.00 |
| drug881 | ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost Wiki | 1.00 |
| drug880 | ChAdOx1 nCoV-19 (Abs 260) Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4102 | Two dose MenACWY vaccine min. 4 weeks apart Wiki | 1.00 |
| drug2333 | MenACWY vaccine Wiki | 1.00 |
| drug890 | ChAdox1 n-CoV-19 (Abs 260) vaccine low dose Wiki | 1.00 |
| drug882 | ChAdOx1 nCoV-19 (qPCR) Wiki | 1.00 |
| drug3442 | SARS-CoV-2 rS/Matrix-M1 Adjuvant Wiki | 0.71 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in healthy UK volunteers.
Description: Number of virologically confirmed (PCR positive) symptomatic cases of COVID-19
Measure: Assess the efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19 in adults aged 18 years and older. Time: Study duration (12 months from last vaccination)Description: Occurrence of serious adverse events (SAEs) throughout the study duration.
Measure: Assess the safety of the candidate vaccine ChAdOx1 nCoV-19 in adults and children Time: Study duration (12 months from last vaccination)Description: Occurrence of solicited local reactogenicity signs and symptoms for 7 days following vaccination
Measure: Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19: occurrence of solicited local reactogenicity signs and symptoms for 7 days following Time: 7 days post vaccinationDescription: Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following vaccination
Measure: Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19: occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following Time: 7 days post vaccinationDescription: Occurrence of unsolicited adverse events (AEs) for 28 days following vaccination
Measure: Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19: occurrence of unsolicited adverse events (AEs) for 28 days following vaccination Time: 28 days post vaccinationDescription: Frequency of participants with clinically significant changes from baseline for safety laboratory measures (haematology and biochemistry blood results; except groups 4, 6, 9 & 10)
Measure: Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19 through standard blood tests (full blood count, liver and kidney function tests) Time: 6 monthsDescription: Occurrence of disease enhancement episodes
Measure: Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV-19 by measuring the number of disease enhancement episodes Time: Study duration (12 months from last vaccination)Description: Number of hospital admissions associated with COVID-19
Measure: Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19: hospital admissions Time: Study duration (12 months from last vaccination)Description: Number of intensive care unit (ICU) admissions associated with COVID-19
Measure: Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 Time: 6 monthsDescription: Number of deaths associated with COVID-19
Measure: Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19: number of deaths Time: 6 monthsDescription: Proportion of people who become seropositive for non-Spike SARS-CoV-2 antigens during the study
Measure: Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates Time: 6 monthsDescription: Proportion of people diagnosed with severe Covid-19 disease (defined according to clinical severity scales)
Measure: Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring incidence of Covid-19 Time: Study duration (12 months from last vaccination)Description: Quantify antibodies against SARS-CoV-2 spike protein (seroconversion rates)
Measure: Assess humoral immunogenicity of ChAdOx1 nCoV-19: antibody quantification Time: 28 days post vaccinationDescription: Proportion of seroconversion to antibodies against SARS-CoV-2 spike protein at Day 28 post-vaccination
Measure: Assess humoral immunogenicity of ChAdOx1 nCoV-19: seroconversion Time: 28 days post vaccinationDescription: Interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISpot) responses to SARS-CoV-2 spike protein
Measure: Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays (groups 1, 2, 3, 7 and 8 only) Time: 6 monthsDescription: Occurrence of solicited local reactogenicity signs and symptoms for 7 days following booster vaccination
Measure: Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1, 2, 7 and 8 only): local reactogenicity Time: 7 days post vaccinationDescription: Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following booster vaccination
Measure: Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only): systemic reactogenicity Time: 7 days post vaccinationDescription: Occurrence of unsolicited adverse events (AEs) for 28 days following booster vaccination
Measure: Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only) Time: 28 days post vaccinationDescription: Frequency of participants with clinically significant changes from baseline from pre-booster for safety laboratory measures (haematology and biochemistry blood results)
Measure: Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only) through standard blood tests (full blood count, liver and kidney function tests) Time: 6 monthsDescription: Antibodies against SARS-CoV-2 spike protein at Day 56 post-vaccination (seroconversion rates)
Measure: Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only) via seroconversion Time: 56 days post vaccinationDescription: Proportion of seroconversion to antibodies against SARS-CoV-2 spike protein at Day 56 post-vaccination
Measure: Assess the safety and immunogenicity of a booster dose of ChAdOx1 nCoV-19 in older adults aged 56 years or older (two-dose schedules for groups 1 and 2 only) Time: 56 days post vaccinationDescription: Virus neutralising antibody (NAb) assays against live and/or pseudotype SARS-CoV-2 virus
Measure: Exploratory Immunology by virus neutralising antibody assays Time: 6 monthsDescription: Cell analysis by flow cytometry assays
Measure: Exploratory Immunology by flow cytometry Time: 6 monthsDescription: Functional antibody assays
Measure: Exploratory Immunology by functional antibody assays Time: 6 monthsDescription: Anti-vector immunity induced by 1 or 2 doses of ChAdOx1 nCoV-19
Measure: Exploratory Immunology: anti-vector immunity Time: 6 monthsDescription: Reported by weekly survey to collect information about cases amongst household contacts and friends, contact with the general public, infection control procedures
Measure: Measure exposure to COVID-19 Time: 6 monthsDescription: Number of PCR positive cases of COVID-19 infection
Measure: Exploratory efficacy against infection: assess efficacy of the candidate ChAdOx1 nCoV-19 against SARS-CoV-2 infection by PCR Time: 6 monthsDescription: Measure of differences in viral loads between those with severe, mild, and asymptomatic PCR+ SARS-CoV-2 infections
Measure: Exploratory efficacy against infection: assess efficacy of the candidate ChAdOx1 nCoV-19 against SARS-CoV-2 infection Time: 6 monthsDescription: Differences in safety, reactogenicity and immunogenicity profiles between Group 1 in COV001 and Group 5 in COV002 (proportion of Grade 3 solicited AEs, occurrence of fevers, seroconversion rates at D28, neutralising antibody titres and differences in T-cell responses at D14).
Measure: Compare safety, reactogenicity and immunogenicity between different manufacturing batches of ChAdOx1 nCoV-19 used in COV001 and COV002 Time: 6 monthsDescription: Differences in safety, reactogenicity and immunogenicity profiles between Groups 1, 2, and 5A compared with Groups, 7, 8, and 5B, C and D respectively (proportion of Grade 3 solicited AEs, occurrence of fevers, seroconversion rates at D28, neutralising antibody titres and differences in T-cell responses at D14).
Measure: Compare safety, reactogenicity and immunogenicity between different methods for measuring doses Time: 6 monthsDescription: Nasal mucosa IgA levels at D0 and D28 in a subset of individuals
Measure: Assess vaccine induced mucosal immunity: Nasal mucosa IgA levels at D0 and D28 in a subset of individuals Time: 6 monthsDescription: Differences in viral shedding on stool at 7 days and beyond post SARS-CoV-2 positivity
Measure: Compare viral shedding on stool samples of SARS-CoV-2 PCR positive individuals Time: 6 monthsDescription: Differences in antibody titres (ELISA and Neutralising antibodies) in participants who received 1 or 2 doses of ChAdOx1 nCoV-19 (groups 1, 2, 7 and 8)
Measure: Compare immunogenicity of ChAdOx1 nCoV-19 in participants receiving 1 or 2 doses in groups 1, 2, 7 and 8: differences in antibody titres Time: 6 monthsDescription: Longevity of immune responses in participants who received 1 or 2 doses of ChAdOx1 nCoV-19
Measure: Compare immunogenicity of ChAdOx1 nCoV-19 in participants receiving 1 or 2 doses in groups 1, 2, 7 and 8: longevity of immune responses Time: 6 monthsDescription: Differences reactogenicity profile, antibody titres and T-cell responses between groups 5d and 11 and their relationship with anti-vector neutralising antibody titres.
Measure: Describe the impact of previous vaccination with other ChAdOx1 vectored vaccines on safety and immune responses to ChAdOx1 nCoV-19 Time: 6 monthsDescription: Cell-mediated and humoral responses against SARS-Cov-2 These will be measured by the following: Proportion of seroconversion to antibodies (Ab) against SARS-CoV-2 spike protein measured by ELISA. Interferon-gamma enzyme linked immunospot (ELISpot) responses to SARS-CoV-2 spike protein Intracellular Cytokine analyses of CD4 and CD8-specific SARS-CoV-2 spike protein responses Further exploratory immunology
Measure: Assess the cell-mediated and humoral immunogenicity profile of ChAdOx1 nCoV-19 vaccine in HIV infected adults Time: 6 monthsDescription: Relationship between nadir CD4 count vs vaccine immune responses
Measure: Assess whether increasing age and or CD4 nadir are associated with a lack of immune response in HIV infected adults: CD4 count-vaccine immune responses Time: 6 monthsDescription: Relationship between age at enrolment and vaccine immune response
Measure: Assess whether increasing age and or CD4 nadir are associated with a lack of immune response in HIV infected adults: age vs vaccine immune responses Time: 6 monthsDescription: Immune responses to ChAdOx1 nCoV-19 (assessed as described above)
Measure: Assess whether increasing age and or CD4 nadir are associated with a lack of immune response in HIV infected adults Time: 6 monthsDescription: Measured by the following: Occurrence of serious adverse events (SAEs) throughout the study duration Occurrence of solicited local reactogenicity signs and symptoms for 7 days following vaccination Occurrence of solicited systemic signs and symptoms for 7 days following each vaccination Occurrence of unsolicited AEs for 28 days following each vaccination
Measure: Assess the safety of the candidate vaccine ChAdOx1 nCoV-19 in HIV infected adults Time: Study duration (12 months from last vaccination)Description: Change in Total HIV DNA copies per million CD4 T cells
Measure: To assess Impact of vaccination on HIV reservoirs Time: Study duration (12 months from last vaccination)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports